The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma

Australas J Dermatol. 2021 May;62(2):e329-e331. doi: 10.1111/ajd.13499. Epub 2020 Nov 20.

Authors

Yuan-Xiang Liu¹, Jian Zhang², Xiao-Lu Nie³, Yun-Liu Chen¹, Zhao-Yang Wang¹, Zi-Gang Xu¹

Affiliations

¹ Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
² Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
³ Center of Clinical Epidemiology＆Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

PMID: 33216947
DOI: 10.1111/ajd.13499

No abstract available

Publication types

Letter

MeSH terms

Antibiotics, Antineoplastic / pharmacology
Antibiotics, Antineoplastic / therapeutic use
Biopsy / methods
Child, Preschool
Female
Hemangioendothelioma / drug therapy*
Humans
Infant
Infant, Newborn
Kasabach-Merritt Syndrome / drug therapy*
Male
Sarcoma, Kaposi / drug therapy*
Sirolimus / pharmacology*
Sirolimus / therapeutic use
Skin Cream / therapeutic use
Treatment Outcome

Substances

Antibiotics, Antineoplastic
Sirolimus

Supplementary concepts

Kaposiform Hemangioendothelioma